The subject expert committee for Covid-19 has given permission for restricted use of Bharat Biotech's Covid-19 vaccine Covaxin in emergency situation for children in 2-18 years group, India Today reported on Tuesday.
The Hyderabad-based drug maker's two-dose vaccine is already been used in the country's immunisation programme against Covid-19 for those above 18 years of age.
"The firm should submit safety data including the data on AEFI (adverse events following immunisation) and AESI (adverse events of special interest), with due analysis, every 15 days for the first two months and monthly thereafter and also as per requirement of New Drugs & Clinical Trials Rules, 2019," the committee was reported as saying.
The vaccine will be administered in two doses, with a gap of 20 days between the first and second dose, the report said.With this approval, Covaxin is the only vaccine in India approved for use in children who are as young as two years. Earlier, drug maker Zydus Cadila's was the only vaccine to be approved for use in those below 18 years in the country. The vaccine has been permitted for use in 12-18 years age group.
#Covaxin #BharatBiotech #AESI #ZydusCadilas #AEFI #Hybiz
HyBiz Tv is India’s most watched Digital Business Channel with over One Million regular viewers. In the 11 years of its existence, HyBiz Tv has provided a platform for business houses to promote, project and propagate their products and services. Corporate videos, promotional videos, interviews, ad- films, events coverage, current relevant news, meaningful discussions on contemporary subjects have given the audience relevant content which has helped in the rapid growth of the viewership. Clients from both the Telugu states and across the country have reaped rich dividends by engaging HyBiz Tv and now this has spread all over the country..
► Watch More Business Videos at India's Leading online business channel [ Ссылка ]
► like us on Facebook: [ Ссылка ]
► Watch More Videos on [ Ссылка ]
► Subscribe to HYBIZTV Channel: goo.gl/EEXqfu
►Follow us on Twitter [ Ссылка ]
